To assess the potential impact of USP22 on PML-RARα-mediated APL differentiation, WT, CRISPR/Cas9 control and USP22 KO NB4 cells were exposed to clinical and subclinical doses of ATRA, followed by immunoblotting of PML-RARα. This evidence concerns the gene RARA and acute promyelocytic leukemia.